Document is current
Any future updates will be listed below
-
Authors
Elsallab, Magdi http://orcid.org/0000-0001-9574-3496
Maus, Marcela V. http://orcid.org/0000-0002-7578-0393
- License Information
-
More Information
Article History
Received: 17 January 2023
Accepted: 5 September 2023
First Online: 26 October 2023
Competing interests
: M.V.M. is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital (some licensed to ProMab) and the University of Pennsylvania (some licensed to Novartis). M.V.M. holds equity in 2Seventy Bio, Century Therapeutics, NexImmune, Oncternal and TCR<sup>2</sup> and has served as a consultant for multiple companies involved in cell therapies. M.V.M. is on the board of directors of 2Seventy Bio. M.V.M. has received grant and/or research support from CRISPR Therapeutics, Kite Pharma, Servier and Novartis. M.E. declares no competing interests.
